氟替美维吸入粉雾剂与布地格福吸入气雾剂治疗稳定期哮喘-慢阻肺重叠综合征的疗效与安全性比较 点击下载
| 论文标题： | 氟替美维吸入粉雾剂与布地格福吸入气雾剂治疗稳定期哮喘-慢阻肺重叠综合征的疗效与安全性比较 |
| 英文标题： | |
| 中文摘要： | 目的 对比氟替美维吸入粉雾剂与布地格福吸入气雾剂治疗稳定期哮喘-慢阻肺重叠综合征（ACOS）的临床疗效与安全性。方法回顾性选取2023年3月－2025年3月于徐州医科大学附属医院确诊并接受规范治疗的157例稳定期ACOS患者的临床资料，根据治疗方案不同分为氟替美维组（80例，在基础治疗的基础上加用氟替美维吸入粉雾剂）和布地格福组（77例，在基础治疗的基础上加用布地格福吸入气雾剂）。比较两组患者治疗前和治疗12、24周时的肺功能指标[第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、一秒率（FEV1/FVC）、FEV1占预计值的百分比（FEV1%pred）、呼气峰流速（PEF）]、炎症指标[外周血嗜酸性粒细胞（EOS）计数、呼出气一氧化氮（FeNO）水平和血清白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）水平]、临床症状评估指标[哮喘控制测试（ACT）评分、慢性阻塞性肺疾病评估测试（CAT）评分、改良英国医学研究委员会呼吸困难量表（mMRC）分级]，记录其治疗24周内的急性加重和不良反应发生情况。结果治疗前，两组患者的肺功能指标、炎症指标、临床症状评估指标比较，差异均无统计学意义（P＞0.05）。治疗12、24周时，两组患者上述指标均较同组治疗前显著改善（P＜0.05），且氟替美维组治疗24周时FEV1、FEV1%pred、PEF以及治疗12、24周时IL-6、TNF-α水平，ACT、CAT评分和mMRC分级的改善均显著优于同期布地格福组（P＜0.05）。治疗24周内，氟替美维组患者的急性加重发生率及急性加重次数均显著低于布地格福组（P＜0.05），两组患者不良反应发生率比较的差异无统计学意义（P＞0.05）。结论氟替美维吸入粉雾剂和布地格福吸入气雾剂均可有效改善ACOS患者的肺功能、减轻其炎症、缓解相关临床症状，且安全性良好；氟替美维吸入粉雾剂在改善远期肺功能、降低系统性炎症标志物水平及防控急性加重方面的优势更明显，更适合稳定期ACOS患者的长期管理。 |
| 英文摘要： | OBJECTIVE To compare the clinical efficacy and safety of Fluticasone furoate/umeclidinium/vilanterol （FF/UMEC/VI） and Budesonide/glycopyrronium/formoterol （BUD/GLY/FOR） in the treatment of stable asthma-chronic obstructive pulmoary disease （COPD） overlap syndrome （ACOS）.METHODS A retrospective analysis was performed on clinical data of 157 patients with stable ACOS who received standardized treatment at the Affiliated Hospital of Xuzhou Medical University from March 2023 to March 2025. Patients were assigned to the FF/UMEC/VI group （ n＝ 80， receiving FF/UMEC/VI in addition to baseline therapy） and the BUD/GLY/FOR group （ n＝ 77， receiving BUD/GLY/FOR in addition to baseline therapy） according to the treatment regimens. The lung function parameters [forced expiratory volume in one second （FEV 1 ）， forced vital capacity （FVC）， FEV 1 /FVC， FEV 1 percentage of predicted value （FEV 1 %pred）， peak expiratory flow （PEF）]， inflammatory markers [peripheral blood eosinophils （EOS） count， fractional exhaled nitric oxide （FeNO） level， serum levels of interleukin-6 （IL-6） and tumor necrosis factor-α （TNF-α）]， and clinical symptom assessment indicators [Asthma Control Test （ACT） scores， COPD Assessment Test （CAT） scores， modified Medical Research Council Dyspnea Scale （mMRC） grades] were compared between the two groups at baseline， week 12 and week 24. The occurrences of acute exacerbations and adverse reactions during the 24-week treatment were documented.RESULTS At baseline， there were no statistically significant differences in lung function parameters， inflammatory markers， or clinical symptom assessment indicators between the two groups （ P ＞0.05）. At weeks 12 and 24， all the above indicators in both groups were significantly improved compared with pre-treatment values in the same group （ P ＜0.05）. The FF/UMEC/VI group showed significantly greater improvements in FEV 1 ， FEV 1 %pred and PEF at week 24， as well as IL-6 and TNF-α levels， ACT and CAT scores， and mMRC grades at both weeks 12 and 24， than the BUD/GLY/FOR group at the corresponding time points （ P ＜0.05）. Within the 24-week treatment， the incidence and frequency of acute exacerbations in the FF/UMEC/VI group were significantly lower than those in the BUD/GLY/FOR group （ P ＜0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups （ P ＞0.05）.CONCLUSIONS Both FF/UMEC/VI and BUD/GLY/FOR can effectively improve lung function， reduce inflammation， and alleviate symptoms in patients with ACOS， and both demonstrate good safety profiles； FF/UMEC/VI shows more pronounced advantages in improving long-term lung function， reducing levels of systemic inflammatory markers， and preventing and controlling acute exacerbations， making it more suitable for the long-term management of patients with ACOS in the stable phase. |
| 期刊： | 2026年第37卷第16期 |
| 作者： | 韩露；赵后彤；陈碧；孙理想 |
| 英文作者： | HAN Lu，ZHAO Houtong，CHEN Bi，SUN Lixiang |
| 关键字： | 氟替美维吸入粉雾剂；布地格福吸入气雾剂；哮喘-慢阻肺重叠综合征；稳定期；肺功能；炎症 |
| KEYWORDS： | Fluticasone furoate/umeclidinium/vilanterol;Budesonide/glycopyrronium/formoterol;asthma-COPD overlap syndrome;stable phase;Lung function;Inflammation |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！